Non-Autologous Blood Derived Products for Chronic Non-Healing Wounds

Because this area has somewhat dense and potentially confusing terminology, it would be helpful for readers to briefly state in the NCD some of the collateral information in the NCA discussion. People will think, well, platelet- rich plasma contains autologous growth factors, and so forth. To whit, why not clearly but briefly state a few phrases such as, "Carrier discretion governs coverage of platelete-rich plasma (PRP) for acute surgical wounds and the use of beclapermin within its FDA- approved indications." Now you have the chance to do so.

Less

I agree with the non-coverage policy as the products (as mentioned) are drug technology and I believe should be covered under the drug benefit. A second comment is that this type of technology/treatment should have some end point of use and check-points of positive outcomes.

Example: I saw a patient who had been using Regranex for 7 years on a leg wound. It was being prescribed for a wound that had no granulation tissue, the bone was exposed, the wound edges epibolized and the woma had NO significant cirulation and abnormal blood sugars. If we want to use technology...it needs to be in concert with appropriate assessment, application and within an appropriate period of time to show positive impact.
Kathleen Thimsen RN ET MSN
30 years in wound management

Less